CHI & Bio-IT World Present the Annual Forum for the Structure-Based Drug Design Community

March 30, 2011 - PRLog -- Cambridge Healthtech Institute and Bio-IT World is pleased to announce the 11th Annual Structure-Based Drug Design (SBDD) conference to be held on June 8-10, 2011 at the Royal Sonesta Hotel Boston in Cambridge, Massachusetts.  This meeting serves as the annual forum for the structure-based drug design community, providing insights on the latest development in computational technology for drug discovery, and puts structure-based molecular approaches into the perspective of targeted therapeutics.

“Building on the well-established reputation among the SBDD community, this conference is a new attempt to bring to focus the latest informatics tools and high performance computing technology for drug design,” said Ming Guo, conference producer for Cambridge Healthtech Institute.  “We are thrilled with the caliber of our speakers, and anticipate a fascinating, interactive and highly educational event.”

This meeting brings together presentations from a preeminent internationally recognized faculty including a keynote presentation by David E. Shaw, Ph.D., who was appointed to the President’s Council of Advisors on Science and Technology by President Clinton in 1994 and once again by President Obama in 2009. Dr. Shaw’s presentation titled “Millisecond-Long Molecular Dynamics Simulations of Proteins on a Special-Purpose Machine” will take place on Friday, June 10.

Additional presentations by:
Ruben Abagyan, Ph.D., Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego

Jascha Blobel, Ph.D., Product Manager, Sales & Product Development, Intelligent Pharma

Stephen K. Burley, M.D., D.Phil., Distinguished Lilly Research Scholar, Lilly Biotechnology Center, Eli Lilly and Company

Dirksen Bussiere, Ph.D., M.B.A., Director, Structural Chemistry, Novartis Institutes for BioMedical Research

Alan Cheng, Ph.D., Senior Scientist, Chemistry Research & Development, Amgen, Inc.

Jean Cui, Ph.D., Associate Research Fellow, Oncology Medicinal Chemistry, Pfizer, Inc.

David C. Dalgarno, Ph.D.,Vice President, Research Technologies, ARIAD Pharmaceuticals, Inc.

Kurt Deshayes, Ph.D., Senior Scientist, Department of Early Discovery Biochemistry, Genentech, Inc.

Ron Dror, Ph.D., Senior Research Scientist and Special Advisor to the Chairman, D. E. Shaw Research

Jonathan Essex, Ph.D., Head, Computational Systems Chemistry; Chairman, Institute for Complex Systems Simulation (ICSS), School of Chemistry, University of Southampton

Andrew C. Good, Ph.D., Distinguished Scientific Fellow, Medicinal Chemistry, Genzyme Corp.

Victor Guallar, Ph.D., ICREA Research Professor, Life Science Department, Barcelona Supercomputing

Roderick Hubbard, Ph.D., Professor, University of York and Vernalis Ltd.

Donald Jacobs, Ph.D., Associate Professor of Physics, Physics and Optical Science, University of North Carolina

Ronald Knegtel, Ph.D., Research Fellow I, Molecular Modeling, Vertex Pharmaceuticals (Europe) Ltd.

Michael Kuiper, Ph.D., Computational Scientist, Victorian Partnership for Advanced Computing

Ravi G. Kurumbail, Ph.D., Research Fellow and Structural Biology Laboratory Head, Pfizer, Inc.

Christopher Langmead, Ph.D., Associate Professor of Computer Science, Carnegie Mellon University

Ronald M. Levy, Ph.D., Board of Governors, Professor of Chemistry & Chemical Biology, Rutgers University

Ryan Lilien, M.D., Ph.D., Assistant Professor, Department of Computer Science & Donnelly Centre for Cellular and Biomolecular Research, University of Toronto

Emanuele Perola, Ph.D., Research Fellow I, Vertex Pharmaceuticals

Charles H. Reynolds, Ph.D., Senior Director, Discovery Technologies, Ansaris

Peter C. Sennhenn, Ph.D., Director Medicinal Chemistry, Proteros Fragments GmbH

Yibing Shan, Ph.D., Senior Scientist, Chemistry and Biology, D. E. Shaw Research

Woody Sherman, Ph.D., Vice President, Applications Science, Schrödinger, Inc.

Lei Shi, Ph.D., Assistant Professor, Department of Physiology and Biophysics, HRH Prince

Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College

Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.

David Thompson, Ph.D., Senior Principal Systems Engineer, Boehringer Ingelheim GmbH

Bruce Tidor, Ph.D., Professor of Biological Engineering and Computational Science, Massachusetts Institute of Technology

Sid Topiol, Ph.D., CSO, Computational and Structural Investigations, 3D-2Drug

Jean-François Truchon, Ph.D., Research Scientist, Chemical Computing Group

Sandor Vajda, Ph.D., Professor of Biomedical Engineering and Chemistry, Director, Biomolecular Engineering Research Center, Boston University

Marcel Verdonk, Ph.D., Director, Computational Chemistry and Informatics, Astex Therapeutics Ltd.

Randy Zauhar, Ph.D., Associate Professor, Chemistry & Biochemistry, University of the Sciences

At the conclusion of day one, delegates are invited to a dinner short course on “Identification of Druggable Sites for Protein-Protein Interaction Targets,” to be hosted by Sandor Vajda, Ph.D., Professor, Departments of Biomedical Engineering and Chemistry, Boston University; and, Dima Kozakov, Ph.D., Research Assistant Professor, Departments of Biomedical Engineering, Boston University.

This conference is co-located with CHI’s 9th Annual Next-Gen Kinase Inhibitors (June 6-8, 2011). CHI is offering reduced conference registrations to those that register for one or both meetings by April 29, 2011.

For additional information on these conferences, call CHI at 781.972.5400 or visit http://www.healthtech.com/sbd

Writers and editors are invited to attend.  To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (http://www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

About Bio-IT World: (http://www.bio-itworld.com)

Part of the Cambridge Healthtech Institute Media Group (http://www.chimediagroup.com),
Bio-IT World magazine is a bimonthly publication that life science and IT/informatics professionals continuously reference to find information, news, and commentary on indispensable technologies and business strategies.  Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Cambridge Healthtech Media Group also hosts daily news and opinion at http://www.bio-itworld.com, a variety of e-newsletters, and a rich compendium of webinars and web symposia. Cambridge Healthtech Media Group is based in Needham, Mass.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com
http://www.healthtech.com/sbd